Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
stocks
Tesla: Board announces new pay package for CEO Elon Musk
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,005.80 | 83.80 | 0.94% |
CAC 40 | 7,632.01 | 85.85 | 1.14% |
DAX 40 | 23,757.69 | 331.72 | 1.42% |
Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
FTSE 100 | 9,128.30 | 59.72 | 0.66% |
HKSE | 24,757.99 | 24.54 | 0.10% |
NASDAQ | 21,053.58 | 403.45 | 1.95% |
Nikkei 225 | 40,544.99 | 254.29 | 0.63% |
NZX 50 Index | 12,813.65 | 129.61 | 1.02% |
S&P 500 | 6,329.94 | 91.93 | 1.47% |
S&P/ASX 200 | 8,745.50 | 81.80 | 0.94% |
SSE Composite Index | 3,599.41 | 16.10 | 0.45% |